{"id":39186,"date":"2017-05-23T00:00:00","date_gmt":"2017-05-22T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/"},"modified":"2020-11-16T16:22:57","modified_gmt":"2020-11-16T15:22:57","slug":"som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/","title":{"rendered":"SOM Biotech licencia su f\u00e1rmaco SOM0226 para la Amiloidosis a la norteamericana Corino Therapeutics"},"content":{"rendered":"<p>SOM Biotech ha recibido un abono inicial y obtendr\u00e1 sucesivos ingresos por hitos y regal\u00edas sobre las ventas netas del producto, a cambio de los derechos globales exclusivos del SOM0226 (CRX-1008), que incluye el uso del f\u00e1rmaco para todos los tipos de ATTR: polineuropat\u00eda amiloide familiar, cardiomiopat\u00eda amiloide familiar, amiloidosis sist\u00e9mica senil, formassft\u00e1lmicas y del sistema nervioso central (SNC).<\/p>\n<p>\u00abEste acuerdo de licencia proporciona una clara validaci\u00f3n del potencial del modelo de negocio de SOM Biotech. El hecho de que los f\u00e1rmacos reposicionados hayan sido ampliamente utilizados en su indicaci\u00f3n original, permite a las personas que sufren enfermedades raras y sin ning\u00fan tratamiento disponible, obtener un desarrollo acelerado de un tratamiento seguro\u201d ,afirma el Dr. Ra\u00fal Insa, director ejecutivo de SOM. Y a\u00f1ade: \u201cSOM ha encontrado un gran equipo directivo en Corino, lo que aporta gran seguridad y experiencia para continuar con el desarrollo del programa. Esta colaboraci\u00f3n nos permitir\u00e1\u00a0ampliar nuestra cartera de productos en un futuro pr\u00f3ximo y empezar la Fase 2 cl\u00ednica de dos nuevos candidatos para el tratamiento de otras enfermedades raras del SNC\u201d.<\/p>\n<p>\u201cEn Corino Therapeutics estamos entusiasmados por colaborar con SOM y su principal programa, SOM0226. Los resultados precl\u00ednicos y primeros resultados cl\u00ednicos demuestran el potencial del f\u00e1rmaco para tratar pacientes con todas las formas de ATTR. Esperamos avanzar en el desarrollo de este prometedor medicamento\u201d declara el equipo directivo de Corino.<\/p>\n<p>La Amiloidosis por Transtiretina es una enfermedad rara degenerativa de origen gen\u00e9tico que afecta principalmente al sistema nervioso y tejido muscular card\u00edaco (miocardio). Esta enfermedad se origina cuando el h\u00edgado y otras zonas del organismo producen la prote\u00edna transtiretina (TTR) mutada, perdiendo as\u00ed su estructura funcional. Esto provoca la acumulaci\u00f3n de agregados t\u00f3xicos en forma de fibras amiloideas que, dependiendo del tipo mutaci\u00f3n, se depositan en diferentes \u00f3rganos como el cerebro, los ri\u00f1ones, nervios perif\u00e9ricos, ojos o miocardio, causando su mal funcionamiento y provocando las diversas formas de la patolog\u00eda.<\/p>\n<p>El agente terap\u00e9utico descubierto por SOM a trav\u00e9s de su plataforma in silico ha sido validado cl\u00ednicamente en un estudio de Fase 2a prueba de concepto en humanos, llevado a cabo en el Hospital Vall d\u2019Hebron de Barcelona. SOM0226 ha obtenido la designaci\u00f3n de f\u00e1rmaco hu\u00e9rfano por la FDA para todos los tipos de ATTR.<br \/>\n\u00a0<\/p>\n<p>\u2022 <a href=\"http:\/\/www.pcb.ub.edu\/portal\/es\/noticies\/-\/noticia\/not_som-biotech-i-vall-d-hebron-finalitzen-amb-exit-un-assaig-clinic-en-pacients-d-un-farmac-per-a-l-amiloidosi?inheritRedirect=false&amp;redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3Dsom%26_cercador_WAR_empleatsempresesportlet_tab%3D3&amp;backURL=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3Dsom%26_cercador_WAR_empleatsempresesportlet_tab%3D3\" target=\"_blank\" rel=\"noopener noreferrer\">Noticia relacionada [+]<\/a><\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p><a href=\"http:\/\/www.pcb.ub.edu\/portal\/es\/cerca?p_p_id=cercador_WAR_empleatsempresesportlet&amp;p_p_lifecycle=0&amp;p_p_state=maximized&amp;p_p_mode=view&amp;p_p_col_id=column-1&amp;p_p_col_count=1&amp;_cercador_WAR_empleatsempresesportlet_jspPage=%2Fhtml%2Fcommon%2Fdetall-empresa.jsp&amp;_cercador_WAR_empleatsempresesportlet_empresaId=ENT_003948&amp;_cercador_WAR_empleatsempresesportlet_redirect=%2Fportal%2Fes%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_mode%3Dview%26_cercador_WAR_empleatsempresesportlet_keywords%3DSOM%26_cercador_WAR_empleatsempresesportlet_tab%3D1\" target=\"_top\" rel=\"noopener noreferrer\">SOM Biotech<\/a>\u00a0\u2013especializada en el reposicionamento de f\u00e1rmacos para tratar enfermedades minoritarias del sistema nervioso\u2013 ha firmado un acuerdo de licencia mundial y exclusivo con la compa\u00f1\u00eda norteamericana <a href=\"http:\/\/corinorx.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Corino Therapeutics<\/a> para el desarrollo cl\u00ednico y comercializaci\u00f3n del f\u00e1rmaco\u00a0SOM0226 para el tratamiento del Amiloidosis por Transtiretina (ATTR). La operaci\u00f3n se cerr\u00f3 despu\u00e9s de que el agente terap\u00e9utico descubierto por la biofarmac\u00e9utica, con sede en el Parc Cient\u00edfic de Barcelona, obtuviese resultados muy prometedores en el estudio cl\u00ednico de Fase 2a.<\/p>\n<p>\u00a0<\/p>\n","protected":false},"author":1,"featured_media":27200,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-39186","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sin-categorizar"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SOM Biotech licencia su f\u00e1rmaco SOM0226 para la Amiloidosis a la norteamericana Corino Therapeutics - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SOM Biotech licencia su f\u00e1rmaco SOM0226 para la Amiloidosis a la norteamericana Corino Therapeutics - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"SOM Biotech\u00a0\u2013especializada en el reposicionamento de f\u00e1rmacos para tratar enfermedades minoritarias del sistema nervioso\u2013 ha firmado un acuerdo de licencia mundial y exclusivo con la compa\u00f1\u00eda norteamericana Corino Therapeutics para el desarrollo cl\u00ednico y comercializaci\u00f3n del f\u00e1rmaco\u00a0SOM0226 para el tratamiento del Amiloidosis por Transtiretina (ATTR). La operaci\u00f3n se cerr\u00f3 despu\u00e9s de que el agente terap\u00e9utico descubierto por la biofarmac\u00e9utica, con sede en el Parc Cient\u00edfic de Barcelona, obtuviese resultados muy prometedores en el estudio cl\u00ednico de Fase 2a. \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-22T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-16T15:22:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/05\/16049226535fa92d1d3eec8.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"461\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"SOM Biotech licencia su f\u00e1rmaco SOM0226 para la Amiloidosis a la norteamericana Corino Therapeutics\",\"datePublished\":\"2017-05-22T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:22:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\\\/\"},\"wordCount\":424,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/16049226535fa92d1d3eec8.jpeg\",\"articleSection\":[\"Sin categorizar\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\\\/\",\"name\":\"SOM Biotech licencia su f\u00e1rmaco SOM0226 para la Amiloidosis a la norteamericana Corino Therapeutics - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/16049226535fa92d1d3eec8.jpeg\",\"datePublished\":\"2017-05-22T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:22:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/16049226535fa92d1d3eec8.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/16049226535fa92d1d3eec8.jpeg\",\"width\":800,\"height\":461},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SOM Biotech licencia su f\u00e1rmaco SOM0226 para la Amiloidosis a la norteamericana Corino Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SOM Biotech licencia su f\u00e1rmaco SOM0226 para la Amiloidosis a la norteamericana Corino Therapeutics - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/","og_locale":"es_ES","og_type":"article","og_title":"SOM Biotech licencia su f\u00e1rmaco SOM0226 para la Amiloidosis a la norteamericana Corino Therapeutics - Parc Cient\u00edfic de Barcelona","og_description":"SOM Biotech\u00a0\u2013especializada en el reposicionamento de f\u00e1rmacos para tratar enfermedades minoritarias del sistema nervioso\u2013 ha firmado un acuerdo de licencia mundial y exclusivo con la compa\u00f1\u00eda norteamericana Corino Therapeutics para el desarrollo cl\u00ednico y comercializaci\u00f3n del f\u00e1rmaco\u00a0SOM0226 para el tratamiento del Amiloidosis por Transtiretina (ATTR). La operaci\u00f3n se cerr\u00f3 despu\u00e9s de que el agente terap\u00e9utico descubierto por la biofarmac\u00e9utica, con sede en el Parc Cient\u00edfic de Barcelona, obtuviese resultados muy prometedores en el estudio cl\u00ednico de Fase 2a. \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2017-05-22T23:00:00+00:00","article_modified_time":"2020-11-16T15:22:57+00:00","og_image":[{"width":800,"height":461,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/05\/16049226535fa92d1d3eec8.jpeg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"adminpcb","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"SOM Biotech licencia su f\u00e1rmaco SOM0226 para la Amiloidosis a la norteamericana Corino Therapeutics","datePublished":"2017-05-22T23:00:00+00:00","dateModified":"2020-11-16T15:22:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/"},"wordCount":424,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/05\/16049226535fa92d1d3eec8.jpeg","articleSection":["Sin categorizar"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/","url":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/","name":"SOM Biotech licencia su f\u00e1rmaco SOM0226 para la Amiloidosis a la norteamericana Corino Therapeutics - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/05\/16049226535fa92d1d3eec8.jpeg","datePublished":"2017-05-22T23:00:00+00:00","dateModified":"2020-11-16T15:22:57+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/05\/16049226535fa92d1d3eec8.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/05\/16049226535fa92d1d3eec8.jpeg","width":800,"height":461},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/som-biotech-licencia-su-farmaco-som0226-para-la-amiloidosis-a-la-norteamericana-corino-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"SOM Biotech licencia su f\u00e1rmaco SOM0226 para la Amiloidosis a la norteamericana Corino Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/39186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=39186"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/39186\/revisions"}],"predecessor-version":[{"id":45277,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/39186\/revisions\/45277"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/27200"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=39186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=39186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=39186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}